DS
KROS icon

DRW Securities’s Keros Therapeutics KROS Stock Holding History

DRW Securities’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-464,895
Closed -$4.74M – 1195
2025
Q1 		$4.74M Buy
+464,895
New +$5.4M 0.13% 99

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

DRW Securities's KROS Position: Q2 2025 in Review

DRW Securities sold out of Keros Therapeutics (KROS) in Q2 2025, closing a stake of 464,895 shares — an estimated $4.74M sold.

DRW Securities first reported a position in KROS in Q1 2025 and held it in 1 quarter. The position peaked at $4.74M in Q1 2025. 139 funds tracked by Wall St. Rank hold KROS as of Q2 2025.

  • DRW Securities reported no remaining Keros Therapeutics position as of Q2 2025 after selling out during the quarter.
  • DRW Securities sold 464,895 Keros Therapeutics shares in Q2 2025, an estimated $4.74M.
  • DRW Securities first reported a position in Keros Therapeutics in Q1 2025 and held it in 1 quarter.
  • DRW Securities's Keros Therapeutics position peaked at $4.74M in Q1 2025.
  • 139 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2025.

Based on DRW Securities's 13F filing for Q2 2025, filed 14 Aug 2025.